Episode Details

FDA Approves New Weight-Loss Pill: Eli Lillys Orforglipron (Foundayo)

The FDA has given the green light to Eli Lillys new weight-loss pill, Orforglipron (Foundayo), for treating obesity and related issues. This oral GLP-one drug mimics a hormone to curb appetite and boost fullness, offering a once-daily option without food or water hassles. Shipping begins this Friday, April sixth, making it the latest in a wave of non-injectable weight-loss meds. Experts praise its flexibility and potential for better treatment adherence. The pill could cost as low as $25 a month with insurance and a Lilly discount card, or up to $349 based on dose. The FDAs speedy new program reviewed the pill in just fifty days, echoing Decembers nod for a Wegovy pill version. This approval is reshaping obesity care, dropping barriers and speeding access.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/1ed6fc2150b30e75